Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: The poor prognosis associated with ovarian cancer is primarily the result of delayed diagnosis and the lack of an effective treatment for advanced disease. Use of novel immunotherapy strategies are being evaluated that work to enhance local and systemic immune responses against cancer cells and can possibly work together with traditional cytotoxic chemotherapy regimens to produce more effective treatment options. Methods: In the present study, we describe a gene‐based therapy whereby the anticancer cytokine interleukin‐12 gene (pmIL‐12) is formulated with a synthetic polymeric delivery vehicle (PPC) and administered intraperitoneally into a mouse model of disseminated ovarian cancer. Results: The administration of pmIL‐12/PPC in tumor‐bearing mice was associated with a shift towards a Th1 immune state, including significant increases in murine IL‐12 (mIL‐12) and interferon (IFN)‐γ (mIFN‐γ) in ascites fluid, with little change in systemic levels of these proteins. The mIL‐12 protein was detectable for several days and could be reintroduced with subsequent injections. We show that treatment delayed the onset of ascites formation and improved survival in a dose‐dependent manner. A significant decrease in vascular endothelial growth factor was associated with pmIL‐12/PPC delivery and believed to play a predominant role in inhibiting ascites accumulation. Administration of pmIL‐12/PPC was associated with minimal toxicity and, when combined with standard chemotherapies, resulted in additive improvement in survival. Conclusions: Taken together, these results suggest that pmIL‐12/PPC may be an effective strategy for inhibiting progression of disseminated ovarian cancer and may offer a new option for treatment of advanced disease that can be used to complement standard therapies. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · cited 2×
“This cell line has been modified by the stable transformation of vascular endothelial growth factor (VEGF)164 and enhanced green fluorescent protein (GFP) [28].”
BackgroundSangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.059 · Cited by 320
Cited by
Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond)
Lächelt, U., & Wagner, E. (2015) · Chemical Reviews · doi:10.1021/cr5006793 · Cited by 600
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundLocalized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
Polyethylenimine (PEI) in gene therapy: Current status and clinical applications
Casper, J., Schenk, S. H., Parhizkar, E., Detampel, P., Dehshahri, A., & Huwyler, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.001 · Cited by 340
Glassman, C. R., Mathiharan, Y. K., Jude, K. M., Su, L., Panova, O., Lupardus, P. J., Spangler, J. B., Ely, L. K., Thomas, C., Skiniotis, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.018 · Cited by 181
Metadata
- Authors
- Fewell, J. G., Matar, M. M., Rice, J. S., Brunhoeber, E., Slobodkin, G., Pence, C., Worker, M., Lewis, D. H., & Anwer, K.
- Venue
- The Journal of Gene Medicine
- Publisher
- Wiley
- Published
- 2009-06-08
- Volume
- 11
- Issue
- 8
- Pages
- 718-728
- ISSN
- 1099-498X (ISSN-L)
- 1521-2254
- OpenAlex
- W1975836245
- Cited by
- 50
- References
- 2
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.